165 related articles for article (PubMed ID: 34635925)
1. Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma.
Zhou B; Gao S
Cancer Immunol Immunother; 2022 May; 71(5):1183-1197. PubMed ID: 34635925
[TBL] [Abstract][Full Text] [Related]
2. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
Wu C; Rao X; Lin W
Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
[TBL] [Abstract][Full Text] [Related]
3. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive characterization of MUC16 mutations in lung adenocarcinoma for immunotherapies and prognosis: An observational study.
Liu T; Wu L; Liu J; Chen H; Zhu B; Qiao D; Zhu Y; Liu T; Chen Q; Hu A
Medicine (Baltimore); 2023 Nov; 102(44):e35481. PubMed ID: 37932988
[TBL] [Abstract][Full Text] [Related]
5. Immune- and Stemness-Related Genes Revealed by Comprehensive Analysis and Validation for Cancer Immunity and Prognosis and Its Nomogram in Lung Adenocarcinoma.
Chen M; Wang X; Wang W; Gui X; Li Z
Front Immunol; 2022; 13():829057. PubMed ID: 35833114
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of the association between tumor-infiltrating immune cells and the prognosis of lung adenocarcinoma.
Pan Y; Sha Y; Wang H; Zhuang H; Ren X; Zhu X; Wei X
J Cancer Res Ther; 2020; 16(2):320-326. PubMed ID: 32474519
[TBL] [Abstract][Full Text] [Related]
7. Systematic construction and validation of an immune prognostic model for lung adenocarcinoma.
Luo C; Lei M; Zhang Y; Zhang Q; Li L; Lian J; Liu S; Wang L; Pi G; Zhang Y
J Cell Mol Med; 2020 Jan; 24(2):1233-1244. PubMed ID: 31779055
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Analysis and Reinforcement Learning of Hypoxic Genes Based on Four Machine Learning Algorithms for Estimating the Immune Landscape, Clinical Outcomes, and Therapeutic Implications in Patients With Lung Adenocarcinoma.
Sun Z; Zeng Y; Yuan T; Chen X; Wang H; Ma X
Front Immunol; 2022; 13():906889. PubMed ID: 35757722
[TBL] [Abstract][Full Text] [Related]
9. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
[TBL] [Abstract][Full Text] [Related]
10. Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.
Yi M; Li A; Zhou L; Chu Q; Luo S; Wu K
Cancer Immunol Immunother; 2021 Jun; 70(6):1705-1719. PubMed ID: 33386920
[TBL] [Abstract][Full Text] [Related]
11. Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.
Bao X; Shi R; Zhao T; Wang Y
J Mol Med (Berl); 2020 Jun; 98(6):805-818. PubMed ID: 32333046
[TBL] [Abstract][Full Text] [Related]
12. CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma.
Li Z; Feng Y; Li P; Wang S; Liu X; Xia S
Int J Gen Med; 2022; 15():3809-3826. PubMed ID: 35418778
[TBL] [Abstract][Full Text] [Related]
13. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
16. Independent Prognostic Potential of GNPNAT1 in Lung Adenocarcinoma.
Zheng X; Li Y; Ma C; Zhang J; Zhang Y; Fu Z; Luo H
Biomed Res Int; 2020; 2020():8851437. PubMed ID: 33178836
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a MUC16 mutation-associated immune prognostic model for lung adenocarcinoma.
Liu H; Xin T; Duan H; Wang Y; Shao C; Zhu Y; Wang J; He J
Aging (Albany NY); 2023 Jun; 15(12):5650-5661. PubMed ID: 37341998
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
Wang W; Ren S; Wang Z; Zhang C; Huang J
Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
[TBL] [Abstract][Full Text] [Related]
19. A promising prognostic signature for lung adenocarcinoma (LUAD) patients basing on 6 hypoxia-related genes.
Luo J; Du X
Medicine (Baltimore); 2021 Dec; 100(50):e28237. PubMed ID: 34918689
[TBL] [Abstract][Full Text] [Related]
20. Significance of Spliceosome-Related Genes in the Prediction of Prognosis and Treatment Strategies for Lung Adenocarcinoma.
Yang Y; Huang T; Fan Y; Lu H; Shao J; Wang Y; Shen A
Biomed Res Int; 2022; 2022():1753563. PubMed ID: 36389112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
